

Title:

Association of celiac disease in patients with multiple sclerosis in Tuscany

Authors:

Barbara Piccini, Monica Olivelli, Maria Pia Amato, Sabina Bartalini, Mario Falcini, Marta Giannini, Eliana Magnani, Luca Massacesi, Anna Maria Repice, Marina Vascotto, Salvatore Grosso

DOI: 10.17235/reed.2020.6123/2018

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Piccini Barbara, Olivelli Monica, Amato Maria Pia, Bartalini Sabina, Falcini Mario, Giannini Marta, Magnani Eliana, Massacesi Luca, Repice Anna Maria, Vascotto Marina, Grosso Salvatore. Association of celiac disease in patients with multiple sclerosis in Tuscany. Rev Esp Enferm Dig 2020. doi: 10.17235/reed.2020.6123/2018.



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

OR breve 3123 inglés

Association of celiac disease in patients with multiple sclerosis in Tuscany

Piccini Barbara¹, Ulivelli Monica², Amato Maria Pia³, Bartalini Sabina⁴, Falcini Mario⁵, Giannini Marta⁶, Magnani Eliana⁷, Massacesi Luca⁸, Repice Anna Maria⁷, Vascotto Marina⁹ and Grosso Salvatore¹⁰

¹Tuscany Regional Centre of Pediatric Diabetes. Pediatric Department. Meyer Children's Hospital. Florence, Italy. ²Neurology and Neurophysiopathology Department. Center for Multiple Sclerosis. University of Siena. Siena, Italy. ³Department of NEUROFARBA. Section Neurosciences. University of Florence, Florence. Italy. Institute Don Gnocchi. Florence, Italy. ⁴Neurology and Neurophysiopathology Department. Center for Multiple Sclerosis. University Hospital Santa Maria alle Scotte. Siena, Italy. ⁵Neurology Department. Santo Stefano Hospital. Prato, Italy. ⁶Department of NEUROFARBA. Section Neurosciences. University of Florence. Florence, Italy. ⁷Division Neurology 2. Careggi University Hospital. University of Florence. Florence, Italy. ⁸Department of Neurosciences. Careggi University Hospital. University of Florence. Florence, Italy. ⁹Clinical Pediatrics. Department of Pediatrics. University Hospital Santa Maria alle Scotte. Siena, Italy. ¹⁰ Clinical Pediatrics. Department of Pediatrics. University of Siena. Siena, Italy

Received: 26/12/2018

Accepted: 18/09/2019

Correspondence: Barbara Piccini. Tuscany Regional Centre of Pediatric Diabetes. Pediatric Department. "A. Meyer" University Children's Hospital. Viale Pieraccini, 24 I-50139 Florence, Italy
e-mail: b.piccini@meyer.it

Funding/support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author's contributions: PB, UM and GS wrote the manuscript, researched data and contributed to the discussion. BS, FM, AMP, GM, ME, RAM, ML and VM researched data. UM and ML contributed to the discussion and edited the manuscript. PB is the guarantor of this work and therefore, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

ABSTRACT

Background and study purpose: to describe the comorbidity of celiac disease among a large cohort of multiple sclerosis patients in Tuscany.

Methods: the association of celiac disease among multiple sclerosis adult patients (n=2050) was retrospectively evaluated.

Results: 13 patients were diagnosed with celiac disease, the female:male ratio was 3.3:1 and the median age at diagnosis was 34.2 years (SD 13). Seventy-seven per cent of subjects complained about gastrointestinal symptoms. IgA anti-transglutaminase was positive in 85 % of cases and there was 70 % of villous atrophy.

Conclusions: the frequency of celiac disease among multiple sclerosis patients examined was lower than in the general population, 0.6 % vs 1 % (p = 0.65).

Keywords: Celiac disease. Multiple sclerosis. Epidemiology. Comorbidity.

INTRODUCTION

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS). Multiple sclerosis-like diseases and a headache associated with brain white-matter lesions (WMLs), which is documented by magnetic resonance imaging (MRI), have been reported in celiac disease (CD) patients (1). No conclusive data support the hypothesis that there is an increased prevalence of MS in patients with CD and of CD in patients with MS. The possible relationship between CD and MS was first recorded in 1965, when the pathogenesis of CD was not completely understood (2). MS and CD share common aspects of a dysregulation of the immune system and they are both inflammatory diseases due to T cell-mediated immunity. The aim of this study was to describe the association of CD among a large cohort of MS patients in Tuscany, compared to the prevalence of CD among the general population.

METHODS

The frequency of CD was retrospectively evaluated among a cohort of 2050 adult patients with MS followed-up during 2016 that were included in the database of the Centers for the diagnosis and treatment of MS in Firenze, Prato and Siena. MS cases were diagnosed between 1985 and 2015, based on the McDonald criteria and subsequent revisions (3).

Patients with the following characteristics were analyzed: gastrointestinal or extra-intestinal symptoms suggestive of CD and/or with iron or vitamin deficiency, serologic tests for CD including tissue transglutaminase IgA antibodies (tTG-IgA), anti-endomysium IgA antibodies (EMA) and/or antibodies against deaminated gliadin peptides (DGP) and the dosage of total IgA levels. An esophagogastroduodenoscopy (EGDS) with small intestine biopsies was performed in subjects with a positive serology, in order to confirm CD diagnosis. The diagnosis was made according to the revised criteria of the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) modified in 1990 (4) and after 2012, according to the new ESPGHAN guidelines (5). A CD prevalence of 1:100 was considered in the general population, based on regional differences in Europe where the prevalence varies from 0.3 % in Germany to 2.4 % in Finland (6). Statistical significance was calculated using 2 x 2 contingency tables and the χ^2 test and corrected with the Fisher exact test when sample sizes were small. Values of $p < 0.05$ were considered as significant.

RESULTS

CD was diagnosed in 13/2050 patients attending 4 MS centers in 3 hospitals in Tuscany region, including 3 males with a median age at CD diagnosis 34.2 years (SD 13) (Table 1). The median age at MS diagnosis was 28.8 years (SD 10.8) and 77 % of patients were female (F:M 3.3:1). Most patients were self-sufficient and in the classification of MS subtypes, the relapsing-remitting form was the most common (61 % of cases). Thirty-one per cent of patients were first diagnosed with CD and they started a gluten free diet (GFD) before being diagnosed with MS, 54 % of patients were diagnosed with CD after MS and 15 % of patients were diagnosed with CD and MS simultaneously. Seventy-seven per cent of the subjects complained about gastrointestinal symptoms. tTG-IgA levels were measured in all patients and tested positive in 85 % of cases. Patient 11 was negative for tTG IgA, EMA and DGP and was treated ab initio with monoclonal antibodies. The negative tests results were in contrast to the presence of histologically documented atrophic lesions (Marsh-Oberhuber 3C) (7) and with gastrointestinal symptoms consistent with CD. Even though HLA-DQ2/DQ8 were negative. Patient 13

complained about abdominal pain that disappeared after gluten elimination, despite negative CD antibodies. This factor, a positive family history of CD and the presence of HLA-DQ2 homozygosity suggested a potential CD. Duodenal biopsies were performed in 12/13 patients (one patient refused). 70 % of subjects had a histological pattern indicative of CD with villous atrophy (Marsh-Oberhuber 3 A, B or C). Patient 10 had mild histological lesions (Marsh 1), positive IgA-tTG and DGP antibodies, gastrointestinal symptoms and positive DQ2, indicating a potential CD. Patient 4 presented had a normal duodenal histology but moderate chronic gastritis, positive IgA-tTG and EMA, a permissive haplotype (DQ2 positive) and gastrointestinal symptoms such as diarrhea. Thus, CD was suspected. Patient 13 had potential CD, as mentioned previously. DQ2 and DQ8 were investigated in 46 % of cases. Predisposing HLA-DQ2 and HLA-DQ8 were negative in just one patient (patient 11). All patients with permissive haplotype showed DQ2.

Only patient 11 repeated EGDS after 10 months of GFD and the atrophic lesions had reverted from Marsh-Oberhuber type 3C to type 1. This patient presented with negative serology without a predisposing haplotype and a third endoscopy was not performed. In conclusion, a CD diagnosis was made in 13/2050 patients with MS, with a prevalence of 0.6 % in the cohort of patients considered. There were no differences between CD prevalence among MS patients and the general population (p 0.65).

DISCUSSION

The present study does not support an increased frequency of CD among MS patients. Moreover, the data surrounding clinical presentation of CD among MS patients mainly indicates an atypical presentation with non-specific gastrointestinal symptoms and extraintestinal manifestations. In this study, gastrointestinal symptoms were present in 77 % of patients and 38 % of subjects had diarrhea as the main symptom.

Since 1966, a variety of neurological disorders have been reported in association with CD (8). The mechanisms implicated in the pathogenesis of neurological disorders associated with CD are not completely understood, due to the fact that only some subjects develop CNS symptoms and the extreme variability of these symptoms. TG6 represents a useful marker of the neurological manifestations in CD patients (9). MS and CD are inflammatory T-cell-mediated autoimmune diseases. However, the evidence is insufficient to support an increased frequency of CD among MS patients and conversely of MS among CD patients, despite these

shared etiological aspects. Nicoletti et al. (10) evaluated the presence of CD related antibodies in 217 patients with MS and 200 healthy controls and there was only one control with CD specific antibodies. On the other hand, Rodrigo et al. (11) reported an increased prevalence of biopsy-proven CD in 8 out of 72 MS patients (11.1 %). Ludvigsson et al. (12) evaluated the comorbidity of CD-neurodegenerative/neuroinflammatory diseases using data from the Swedish national register. CD was positively associated with polyneuropathy but not with MS. The strength of the present study is the large sample size, the expertise on immunological diseases of highly specialized centers in a third level hospital and the multidisciplinary approach. Some limitations must be highlighted: (i) only patients with evocative symptoms underwent serological screening and it is possible that CD was under-diagnosed due to the fact that cases with paucisymptomatic or silent CD were missed; (ii) HLA-DQ2 or HLA-DQ8 molecules were investigated in only 46 % of CD-MS patients; and (iii) it should be taken into account that the positivity of serological markers for CD in these patients could be influenced by MS therapies.

In conclusion, this study highlights the usefulness to implement a case-finding strategy in order to address the issue of comorbidity CD-MS. HLA-DQ2 and HLA-DQ8 typing would allow the identification of patients with MS who are at risk and should be periodically screened for CD. This is likely due to the strong negative predictive value and the different HLA class II susceptibility to MS (DQB1*0602 or DR2). On the other hand, CD should be retained as a red flag for a particular diagnostic caution in patients with non-specific MS symptoms and/or WMLs.

REFERENCES

1. Hadjivassiliou M, Grünewald RA, Lawden M, et al. Headache and CNS white matter abnormalities associated with gluten sensitivity. *Neurology* 2001;56:385-88. DOI: 10.1212/WNL.56.3.385
2. Shatin R. Gluten and multiple sclerosis. *Br Med J* 1965;1:1433-4. DOI: 10.1136/bmj.1.5447.1433-d
3. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the Mc Donald criteria. *Ann Neurol* 2011;69:292-302. DOI: 10.1002/ana.22366

4. Revised criteria for diagnosis of coeliac disease. Report of working group of European Society of Pediatric Gastroenterology and Nutrition. Arch Dis Child 1990;65:909-11. DOI: 10.1136/adc.65.8.909
5. Husby S, Koletzko S, Korponay-Szabó IR, et al; ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136-60. DOI: 10.1097/MPG.0b013e31821a23d0
6. Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of celiac disease in Europe: results of a centralized, International mass screening project. Ann Med 2010;42:587-95. DOI: 10.3109/07853890.2010.505931
7. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of celiac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999;11:1185-94. DOI: 10.1097/00042737-199910000-00019
8. Cooke WT, Smith WT. Neurological disorders associated with adult coeliac disease. Brain 1966;89:683-722. DOI: 10.1093/brain/89.4.683
9. Hadjivassiliou M, Rao DG, Grinewald RA, et al. Neurological Dysfunction in Coeliac Disease and Non-Coeliac Gluten Sensitivity. Am J Gastroenterol 2016;111:561-7. DOI: 10.1038/ajg.2015.434
10. Nicoletti A, Patti F, Lo Fermo S, et al. Frequency of celiac disease is not increased among multiple sclerosis patients. Mult Scler 2008;14:698-700. DOI: 10.1177/1352458507087268
11. Rodrigo L, Hernández-Lahoz C, Fuentes D, et al. Prevalence of celiac disease in multiple sclerosis. BMC Neurol 2011;11:31. DOI: 10.1186/1471-2377-11-31
12. Ludvigsson JF, Olsson T, Ekblom A, et al. A population-based study of celiac disease, neurodegenerative and neuroinflammatory diseases. Aliment Pharmacol Ther 2007;25:1317-27. DOI: 10.1111/j.1365-2036.2007.03329.x

Table 1. Clinical data, serology, histology and haplotype among 13 patients with MS/CD

	Sex	Age at CD diagnosis	Histology*	Serology	Genetics DQ2/DQ8	GI symptoms	Extra-GI symptoms	Associated diseases
P1	m	29	3A	tTG +	Not performed	Pyrosis	Anemia	No
P2	m	51	3B	tTG +	Not performed	Diarrhea - bloating	Asthenia	No
P3	f	30	Not performed	tTG + EMA +	DQ2	Diarrhea-stypsis	No	No
P4	f	46	Normal (duodenal, chronic gastritis)	tTG + EMA+	DQ2	Diarrhea	No	No
P5	f	2	3C	tTG +	Not performed	No	No	T1DM
P6	f	30	3C	tTG +	Not performed	No	No	T1DM
P7	f	40	3C	tTG +	Not performed	No	Asthenia-anemia	No
P8	f	30	3C	tTG + EMA+	Not performed	Stypsis dyspepsia	No	Depression
P9	m	46	3C	tTG +	DQ2	Pyrosis bloating	Anemia	No
P10	f	43	1	tTG + DGP+	DQ2	Acholic feces	Anemia	No
P11	f	38	3C	tTG- DGP- EMA -	DQ2/DQ8 negative	Abdominal pain	No	No
P12	f	40	3C	tTG +	Not performed	Abdominal pain, diarrhea, weight loss	No	No
P13	f	20	Normal	tTG - EMA -	DQ 2	Dyspepsia abdominal pain	No	No

*Modified Marsh-Oberhuber classification (7).

m: male; f: female; tTG: antibodies anti transglutaminase; EMA: antibodies anti- endomysial;
DGP antibodies anti deamidated gliadin peptide; GI: gastrointestinal; T1DM type 1 diabetes
mellitus.

Accepted Article